Cortical atrophy patterns in myelin oligodendrocyte glycoprotein antibody-associated disease.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
revised:
07
06
2024
received:
27
02
2024
accepted:
09
06
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
26
7
2024
Statut:
aheadofprint
Résumé
Global brain volume changes in patients with myelin oligodendrocyte glycoprotein antibody-associated disease compared with healthy controls (HC) could be revealed by magnetic resonance imaging, but specific atrophy patterns of cortical structures and relation to cognitive impairment are not yet comprehensively known. Thus, we aimed to investigate cortical thickness differences in patients with myelin oligodendrocyte glycoprotein antibody-associated disease compared with HC. 3-Tesla brain magnetic resonance imaging was performed in 23 patients with myelin oligodendrocyte glycoprotein antibody-associated disease and 49 HC for voxel-wise group comparisons and neuropsychological testing in patients. Surface-based morphometry with region of interest-based surface analysis and region of interest-based extraction of cortical thickness was performed in patients compared with HC and in patient subgroups with and without cognitive impairment. Comparing patients with myelin oligodendrocyte glycoprotein antibody-associated disease with HC, exploratory surface-based morphometry demonstrated cortical volume reduction in pericalcarine and lingual cortical regions. Region of interest-based surface analysis specified reduced cortical thickness in the adjacent pericalcarine and orbitofrontal regions in myelin oligodendrocyte glycoprotein antibody-associated disease, as well as reduced temporal cortical thickness in patients with cognitive impairment (n = 10). Patients without cognitive impairment (n = 13) showed only circumscribed cortical brain volume loss compared with HC in the pericalcarine region. In conclusion, cortical atrophy in myelin oligodendrocyte glycoprotein antibody-associated disease was characterized by cortical thickness reduction in the adjacent pericalcarine and orbitofrontal regions, with a tendency of temporal thickness reduction in cognitively impaired patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Reindl M, Di Pauli F, Rostásy K, Berger T. The spectrum of MOG autoantibody‐associated demyelinating diseases. Nat Rev Neurol. 2013;9(8):455‐461.
Sechi E, Cacciaguerra L, Chen JJ, et al. Myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022;13:885218.
Dubey D, Pittock SJ, Krecke KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019;76(3):301‐309.
Jurynczyk M, Geraldes R, Probert F, et al. Distinct brain imaging characteristics of autoantibody‐mediated CNS conditions and multiple sclerosis. Brain. 2017;140(3):617‐627.
Cortese R, Battaglini M, Prados F, et al. Clinical and MRI measures to identify non‐acute MOG‐antibody disease in adults. Brain. 2023;146(6):2489‐2501.
Höftberger R, Guo Y, Flanagan EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020;139(5):875‐892.
Ogawa R, Nakashima I, Takahashi T, et al. MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm. 2017;4(2):e322.
Salama S, Khan M, Shanechi A, Levy M, Izbudak I. MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler J. 2020;26(14):1854‐1865.
Duan Y, Zhuo Z, Li H, et al. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS. J Neurol Neurosurg Psychiatry. 2021;92(7):709‐716.
Rechtman A, Brill L, Zveik O, et al. Volumetric brain loss correlates with a relapsing MOGAD disease course. Front Neurol. 2022;13:867190. doi:10.3389/fneur.2022.867190
Messina S, Mariano R, Roca‐Fernandez A, et al. Contrasting the brain imaging features of MOG‐antibody disease, with AQP4‐antibody NMOSD and multiple sclerosis. Mult Scler. 2022;28(2):217‐227.
Lotan I, Billiet T, Ribbens A, et al. Volumetric brain changes in MOGAD: a cross‐sectional and longitudinal comparative analysis. Mult Scler Relat Disord. 2023;69:104436.
Zhuo Z, Duan Y, Tian D, et al. Brain structural and functional alterations in MOG antibody disease. Mult Scler J. 2021;27(9):1350‐1363.
Fabri TL, O'Mahony J, Fadda G, et al. Cognitive function in pediatric‐onset relapsing myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD). Mult Scler Relat Disord. 2022;59:103689.
Kogel A‐K, Ladopoulos T, Schwake C, et al. Cognitive impairment in MOGAD is associated with a history of ADEM‐like episodes and cortical atrophy‐ECTRIMS 2022 – poster. Mult Scler J. 2022;28(3_suppl):130‐691.
Fjell AM, Grydeland H, Krogsrud SK, et al. Development and aging of cortical thickness correspond to genetic organization patterns. Proc Natl Acad Sci U S A. 2015;112(50):15462‐15467.
Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15(1):134.
Zimmermann F. Testbatterie zur Aufmerksamkeitsprüfung. PSYTEST; 2002.
Aschenbrenner S, Tucha O, Lange KW. Manual zum RWT (Regensburger Wortflüssigkeits‐Test). Hogrefe; 2000.
Härting C, Wechsler D. Wechsler Memory Scale ‐ Revised (WMS‐R); Deutsche Adaptation der Wechsler Memory Scale – Revised (WMS‐R). Verlag Hans Huber; 2000.
Sturm W. Horn. Leistungsprüfsystem. Hogrefe Verlag; 1993.
Helmstaedter L. Lux. Verbaler Lern‐ und Merkfähigkeitstest. Beltz Test GmbH; 2001.
Penner I, Raselli C, Stöcklin M, Opwis K, Kappos L, Calabrese P. The fatigue scale for motor and cognitive functions (FSMC): validation of a new instrument to assess multiple sclerosis‐related fatigue. Mult Scler J. 2009;15(12):1509‐1517.
Gaser C, Dahnke R, Thompson PM, et al. Title of the paper: CAT‐A Computational Anatomy Toolbox for the Analysis of Structural MRI Data. http://adni.loni.usc.edu/wp‐content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Schmidt P, Gaser C, Arsic M, et al. An automated tool for detection of FLAIR‐hyperintense white‐matter lesions in multiple sclerosis. NeuroImage. 2012;59(4):3774‐3783.
Kazzi C, Alpitsis R, O'Brien TJ, Malpas CB, Monif M. Cognitive and psychopathological features of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody‐associated disease: a narrative review. Mult Scler Relat Disord. 2024;85:105596.
Cabeza R, Nyberg L. Imaging cognition II: an empirical review of 275 PET and fMRI studies. J Cogn Neurosci. 2000;12(1):1‐47.
Ishai A, Ungerleider LG, Martin A, Schouten JL, Haxby JV. Distributed representation of objects in the human ventral visual pathway. Proc Natl Acad Sci. 1999;96(16):9379‐9384.
Bin CE, Kim D, Jeong B, et al. Disrupted structural network of inferomedial temporal regions in relapsing–remitting multiple sclerosis compared with neuromyelitis optica spectrum disorder. Sci Rep. 2022;12(1):5152.
Tillema J, Hulst H, Rocca M, et al. Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: a multicenter study. Mult Scler J. 2016;22(7):901‐909.
Herlin B, Navarro V, Dupont S. The temporal pole: from anatomy to function—a literature appraisal. J Chem Neuroanat. 2021;113:101925.
Fujimori J, Fujihara K, Wattjes M, Nakashima I. Patterns of cortical grey matter thickness reduction in multiple sclerosis. Brain Behav. 2021;11(4):e02050.
Rolls ET. The functions of the orbitofrontal cortex. Brain Cogn. 2004;55(1):11‐29.
Coullon GSL, Emir UE, Fine I, Watkins KE, Bridge H. Neurochemical changes in the pericalcarine cortex in congenital blindness attributable to bilateral anophthalmia. J Neurophysiol. 2015;114(3):1725‐1733.
Budhram A, Mirian A, Sharma M. Meningo‐cortical manifestations of myelin oligodendrocyte glycoprotein antibody‐associated disease: review of a novel clinico‐radiographic spectrum. Front Neurol. 2022;13:1044642.
Gebodh N, Vanegas MI, Kelly SP. Effects of stimulus size and contrast on the initial primary visual cortical response in humans. Brain Topogr. 2017;30(4):450‐460.
Sulpizio V, Committeri G, Lambrey S, Berthoz A, Galati G. Selective role of lingual/parahippocampal gyrus and retrosplenial complex in spatial memory across viewpoint changes relative to the environmental reference frame. Behav Brain Res. 2013;242:62‐75.
Weiner KS, Zilles K. The anatomical and functional specialization of the fusiform gyrus. Neuropsychologia. 2016;83:48‐62.
Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody‐associated disease: international MOGAD panel proposed criteria. Lancet Neurol. 2023;22(3):268‐282.